MedTrace Logo

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

NCT02076477 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2020-03-17

No results posted yet for this study

Summary

This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.

Conditions

  • Oligo-metastatic Stage IV Non-small Cell Lung Cancer

Interventions

RADIATION

concurrent chemoradiotherapy

Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.

DRUG

Docetaxel

Docetaxel:60mg/m2 d1,Given IV

DRUG

pemetrexed

pemetrexed: 500mg/m2 d1,Given IV

DRUG

Cisplatin

Cisplatin：25mg/m2 d1-3，Given IV

Sponsors & Collaborators

  • Mianyang Central Hospital

    collaborator OTHER

  • Cancer Hospital of Guizhou Province

    collaborator OTHER

  • Sichuan Cancer Hospital and Research Institute

    lead OTHER

Principal Investigators

  • JIAHUA LV, MD · Sichuan Cancer Hospital and Research Institute

  • XIAOHU WANG, MD, PhD · Gansu Cancer Hospital

  • XIAOBO DU, MD, PhD · Mianyang Central Hospital

  • BING LU, MD.PhD · Cancer Hospital of Guizhou Province

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076477 on ClinicalTrials.gov